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Abstract The importance of two highly conserved cysteines in 
the human vasoactive intestinal peptide receptor 1 (hVIPR 1) 
was examined. By site-directed mutagenesis each Cys residue 
was converted into Ala or Ser. The mutant and wild-type genes 
were transfected into HEK293 cells and tested for the ability to 
bind VIP and to activate cAMP production. Cys215-Ala/Ser and 
Cys285-Ala/Ser showed at least a 10-fold decrease in binding 
affinity and receptor potency when compared to the wild type. In 
contradiction to the wild-type receptor, both mutations were 
insensitive to dithiothreitol (DTT). The results indicate the 
existence of a disulfide bond between Cys2 1 5 and Cys 2 8 5 , which is 
important for stabilising the receptor in the correct conformation 
for ligand binding and activation. 
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1. Introduction 
The human vasoactive intestinal peptide receptor 1 
(hVIPRl) is a member of the secretin receptor family, which 
belongs to the group of G protein-coupled receptors having 
seven t ransmembrane helices (TM) [1-3]. hVIPRl is activated 
by interaction with the widely distributed neuropeptide vaso-
active intestinal polypeptide (VIP) [4]. The active conforma-
tion results in stimulation of adenylate cyclase via G protein 
coupling and intracellular production of cAMP. Several struc-
tural features are conserved in the entire family of G protein-
coupled receptors (GPCR) , forming the basis of a fundamen-
tal relationship in their functioning. Among the conserved 
structural features, the covalent linking of the first and second 
extracellular loop by a disulfide bond is considered to be 
important for the generation and stabilisation of receptor 
structure in the rhodopsin family, the major and best studied 
family of G P C R s [5]. Convincing evidence for the existence of 
a disulfide bridge between extracellular loop 1 and 2 in the 
secretin receptor family has not yet been provided. 
The purpose of the present study was to examine the im-
portance of cysteines and disulfide bonding for the binding 
and activation of h V I P R l . In addition, the effect of a disulfide 
reducing agent, D T T , on VIP binding was examined. Our 
findings suggest that a disulfide bond is present in the human 
VIP receptor 1 between Cys21° and Cys2 8 5 , and that this link-
age is critical for maintaining a functional conformation. 
*Corresponding author. Fax: (45) 35313955. 
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2. Materials and methods 
2.1. Receptor constructs and site-directed mutagenesis 
The cDNA encoding the human VIP receptor 1 was kindly donated 
by Drs. A. Couvineau and M. Laburthe, INSERM U410, Paris, 
France. The coding region was subcloned into the expression vector 
pcDNA3 from Invitrogen. Mutagenesis was carried out by the overlap 
extension method using Pwo-polymerase (Boehringer Mannheim). 
Identification of all the mutants was confirmed by sequencing (Perkin 
Elmer). 
2.2. Cell culture and transient transfection 
HEK293 cells were grown in MEM (Earl's salt), supplemented with 
10% fetal bovine serum and 1 %o gentamicin. HEK293 cells were 
plated in 200-mm dishes (4X 106 cells/dish) and transiently transfected 
with wild-type cDNA and mutant cDNA, using the CaPC>4 precipi-
tation method. Cells were harvested 72 h after transfection for mem-
brane preparation and VIP-stimulated cAMP production. 
2.3. Preparation of plasma membranes 
Cells from confluent 200 mm culture plates were rinsed with PBS 
buffer and scraped off in the same buffer. After centrifugation, the 
supernatant was resuspended in 15 ml binding buffer containing 20 
mM HEPES, 2 mM CaCl2, 150 mM NaCl, 5 mM EDTA, 1 mg/ml 
Bacitracin and 200 ug/ml bovine serum albumin. The cell suspension 
was homogenised with a polytron for 30 s, centrifuged at 20000Xg 
for 20 min and resuspended in binding buffer. The procedure was 
repeated once and the membranes were resuspended in 10 ml binding 
buffer and stored until use at —80°C. Protein concentration was de-
termined by the Bradford analysis (Bio-Rad). 
2.4. Binding of /1251] VIP to plasma membrane 
The functional properties of wild-type and mutant VIP receptors 
were analysed by [125I]VIP binding to plasma membranes. VIP was 
labelled and purified as described by Martin et al. [6]. Binding reac-
tions were carried out on 10 u,g of membranes in a total volume of 
150 ul with a constant amount of radioiodinated VIP (10~10 M) and 
increasing concentrations of unlabeled VIP (0-10~6 M) for 60 min at 
room temperature. Bound and free radioligands were separated by 
centrifugation. To examine the effect of the reducing agent DTT on 
[125I]VIP binding, wild-type and mutant receptors were incubated with 
10 mM DTT. Data were analysed by non-linear least-square regres-
sion [7]. 
2.5. Intracellular cAMP assay 
Intracellular cAMP levels were assayed with a [125I]cAMP assay 
system from Amersham. HEK293 cells were transfected and seeded 
to 2X 105 cells/well 48 h after transfection. After a further 24 h cells 
were washed with MEM and incubated with 500 ul MEM containing 
0.1 mM isobutyl-methylxanthine (IBMX) for 20 min at 37°C and for 
a further 25 min at 37°C with VIP in increasing concentrations (0 M -
10~6 M). cAMP was extracted by incubating the cells with 50 ul 
trichloroacetic acid and neutralised by 50 ul 0.8 M Tris-base. 
The generation of standard curves and the measurement of cAMP 
levels in supernatant of cell lysates were performed according to the 
manufacturer's instructions. Data were analysed by non-linear least-
square regression [7]. 
3. Results and discussion 
Several sequence alignments have been made in the rhodop-
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Fig. 1. Schematic representation of the human VIP receptor 1, con-
sisting of seven transmembrane helices (TMI-TMVII), an extracellu-
lar N-terminal domain and a C-terminal domain located inside the 
cell. le-3e corresponds to the extracellular loops and li-3i to the in-
tracellular loops. The investigated cysteine residues C215 and C285 
are presented in black. 
sin family and a common feature is the presence of two con-
served cysteines in the first and second extracellular loops 
[8,9]. These two positions are supposed to form a covalent 
linking by a disulfide bridge thereby stabilising the structure 
of the receptor. Two residues, Cys215 in extracellular loop 1 
and Cys285 in extracellular loop 2 of the human VIP receptor 
1 (Fig. 1), corresponding to the highly conserved positions in 
the rhodopsin family, were mutated into alanine (A) or serine 
(S) using site-directed mutagenesis. The wild-type and mutant 
receptors were transfected into HEK293 cells. 
The expression level, binding affinity on purified mem-
branes and production of cAMP on cell lysates from 
C215A/S, C285A/S and wild type were examined. Using the 
equation of Akera and Cheng [10] to calculate the expression 
level (5max), we obtained similar data for C215A/S, C285A/S 
and the wild type (Table 1). However, a marked decrease in 
binding affinity of C215A/S and C285A/S compared to the 
wild-type receptor was observed (Fig. 2). The effect of the 
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Fig. 2. Competitive inhibition of [125I]VIP binding to membrane 
preparation from HEK293 cells, transiently expressing hVIPRl 
(wild type) and mutants, by unlabelled VIP. Data points represent 
the mean ± S.E.M. of 8-13 separate experiments, each made in du-
plicate. The IC50 values for wild type and mutants are given in Ta-
ble 1. 
disulfide reducing agent DTT was examined on wild-type 
and mutant receptors. Incubation of the wild type with 10 
mM DTT caused, in agreement with the findings described 
by Robberecht et al. [11], a loss in VIP binding and receptor 
number, whereas the binding characteristics of the mutant 
receptors were unaffected (data not shown). In accordance 
with our binding data, the dose-response curves for VlP-in-
duced cAMP production in the mutants were shifted 30- to 
300-fold to the right (Fig. 3). 
In a previous study, Gaudin et al. [12] performed a number 
of point mutations in the hVIPRl including C215G and 
C285G. They examined the effect on VIP binding and found 
similar binding affinity of wild type and C215G, whereas bind-
ing to C285G was not detectable. C215G showed a 30-fold 
decrease in expression level compared to the wild type, which 
is in contrast to our findings of a similar expression level for 
wild type and mutants. Their conclusion was, however, that a 
disulfide bridge is not present. A number of explanations can 
be offered to explain the discrepancies between theirs and our 
results: (1) different methods of labelling and purifying the 
radioligand; (2) different buffer systems; (3) different prepa-
rations of plasma membranes; and (4) different cell lines. 
Their binding data were not, as in the present study, sup-
ported by cAMP production to demonstrate receptor activity. 
Furthermore, our findings are in accordance with the reported 
importance of the cysteine bond between extracellular loops 1 
and 2 in the rhodopsin family [13-17]. 
In conclusion, our data suggest the existence of a disulfide 
bond between the two conserved extracellular cysteines (C215 
Table 1 
Binding affinity (IC50), activation (EC50) and receptor number (Bm 
ently expressed in HEK293 cells 
x) for human VIP receptor 1 wild type and Cys residue mutations, transi-
Receptor mutation IC50 (nM)± S.E.M. EC50 (nM)± 
0.6 ±0.4 
18±3 
40 ±21 
75 ±35 
232 ±30 
S.E.M. Smax (Pmc 
2.5 ±0.5 
1.5±0.8 
3.6 ±0.8 
2.4 ±0.9 
4.0 ±0.8 
)l/mg protein) : S.E.M. 
Wild type 
C215A 
C215S 
C285A 
C285S 
3.1 ±0.6 
42±6 
61 ±28 
60 ±25 
62 ±31 
Data represent the mean ± S.E.M. of at least five experiments, each made in duplicate. 
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Fig. 3. VIP-induced cAMP production in HEK293 cells expressing 
wild-type and mutant receptors for hVIPRl. Data points represent 
the mean ± S.E.M. of 4-6 separate experiments, each made in dupli-
cate. The EC50 values for wild type and mutants are given in 
Table 1. 
and C285) in the human VIP receptor 1. By point mutat ion of 
the cysteines, the expression level of the receptor was unaf-
fected, but binding and activation were severely impaired. It is 
likely that the cysteines and the disulfide bridge are important 
for the maintenance of the correct high-affinity structure of 
the receptor. 
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